(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia...
Stats | |
---|---|
今日成交量 | 25.13M |
平均成交量 | 9.60M |
市值 | 10.23B |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0.0600 ( 2020-06-29 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 18.13 |
ATR14 | HKD0.00900 (0.33%) |
音量 相关性
Luye Pharma Group Ltd 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Luye Pharma Group Ltd 相关性 - 货币/商品
Luye Pharma Group Ltd 财务报表
Annual | 2023 |
营收: | HKD6.14B |
毛利润: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2023 |
营收: | HKD6.14B |
毛利润: | HKD4.20B (68.44 %) |
EPS: | HKD0.140 |
FY | 2022 |
营收: | HKD5.98B |
毛利润: | HKD4.14B (69.22 %) |
EPS: | HKD0.170 |
FY | 2021 |
营收: | HKD5.20B |
毛利润: | HKD3.40B (65.32 %) |
EPS: | HKD-0.0422 |
Financial Reports:
No articles found.
Luye Pharma Group Ltd Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
First Dividend | HKD0.0370 | 2016-10-04 |
Last Dividend | HKD0.0600 | 2020-06-29 |
Next Dividend | HKD0 | N/A |
Payout Date | 2020-07-24 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.406 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.99 | -- |
Div. Sustainability Score | 8.62 | |
Div.Growth Potential Score | 4.10 | |
Div. Directional Score | 6.36 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9922.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
2180.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1181.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
0257.HK | Ex Dividend Junior | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
3886.HK | Ex Dividend Junior | 2023-06-27 | Sporadic | 0 | 0.00% | |
1755.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
0798.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
2338.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1313.HK | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
0373.HK | Ex Dividend Junior | 2023-05-04 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0867 | 1.500 | 8.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0209 | 1.200 | 9.30 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0446 | 1.500 | -0.615 | -0.923 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.315 | 0.800 | 8.42 | 6.74 | [1 - 3] |
quickRatioTTM | 0.844 | 0.800 | 9.74 | 7.79 | [0.8 - 2.5] |
cashRatioTTM | 0.398 | 1.500 | 8.90 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.330 | -1.500 | 4.50 | -6.76 | [0 - 0.6] |
interestCoverageTTM | 2.56 | 1.000 | -0.164 | -0.164 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.98 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.671 | -1.500 | 7.32 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.684 | 1.000 | 1.927 | 1.927 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.144 | 1.000 | 9.11 | 9.11 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0821 | 1.000 | -0.655 | -0.655 | [0.2 - 2] |
assetTurnoverTTM | 0.241 | 0.800 | -1.727 | -1.381 | [0.5 - 2] |
Total Score | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.77 | 1.000 | 8.31 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0446 | 2.50 | -0.395 | -0.923 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0387 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.183 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 1.601 | 1.500 | 2.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.112 | 1.000 | 9.69 | 0 | [0.1 - 0.5] |
Total Score | 4.10 |
Luye Pharma Group Ltd
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。